Authors
Latest:
Holistic and Multidisciplinary Approaches to Multiple Myeloma ManagementClosing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Latest:
Dr Kurz on Social Determinants of Health That Contribute to Disparities in Cancer CareRenee Kurz, DNP, FNP-BC, AOCNP, discusses social determinants of health that can contribute to disparities in cancer care, highlighting examples seen throughout New Jersey that emphasize the need for further investigation into this landscape.
Latest:
Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCCSaby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.
Latest:
Make Time for Your Own HealthAlthough graduate medical education at many hospitals includes provisions to ensure that trainees remain physically, emotionally, and mentally healthy, few residents and fellows make use of these resources.
Latest:
Undocumented Immigrants With Cancer Face Unique Care ChallengesUndocumented immigrants continue to face discriminatory policies, which affect those with cancer on emotional, financial, physical, and social levels.
Latest:
Dr Luo on Optimal Initial Chemotherapy Regimens in NUT CarcinomaJia Luo, MD, discusses a retrospective analysis of initial chemotherapy regimens for the treatment of patients with locally advanced and metastatic NUT carcinoma, which was presented at the 2023 IASLC World Conference on Lung Cancer.
Latest:
Dr Basin on the Methods for Investigating Hsp70 Inhibition in Belzutifan-resistant in RCCMichael Basin, MD, discusses the design of a preclinical investigation into the pharmacological inhibition of the molecular chaperone Hsp70 and how it relates to belzutifan resistance in clear cell renal cell carcinoma.
Latest:
Dr. Vail Discusses Emerging Advances in Biomarker Testing in Lung CancerEric Vail, MD, discusses emerging advances in biomarker testing in lung cancer.
Latest:
Overcoming Barriers to TIL Use in Patients With Solid TumorsClosing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Latest:
Emerging Concepts on the Role of Immunotherapy in NSCLCMartin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.
Latest:
Managing TLS and CRS/ICANS: Through the Lens of a First-Year Hematology/Oncology FellowTumor lysis syndrome is an oncologic emergency that every clinician will likely encounter at one time or another, and managing it requires careful consideration of a number of factors.
Latest:
Unmet Needs in the Treatment of HR+/HER2- Breast CancerClosing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.
Latest:
Reducing Burnout Requires an Organizational ResponseA new study suggests that reducing physician burnout requires an organizational-level response that focuses on creating of a medical practice culture that value qualities such as teamwork, open communication, and process improvement.
Latest:
Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast CancerAndrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.
Latest:
Dr. Beitinjaneh on the Evaluation of Tabelecleucel in EBV+ Hematologic MalignanciesAmer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.
Latest:
Dr. Chalabi on the Role of MSI Testing in CRCMyriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,
Latest:
How to Make Clinical Decisions With AI in OncologySpeculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.
Latest:
Dr. Liao on Outcomes With Ivosidenib in Advanced CholangiocarcinomaChih-Yi Liao, MD, discusses outcomes reported with ivosidenib in patients with advanced cholangiocarcinoma.
Latest:
Physicians Must Become Advocates to Play a Role in Community Oncology’s FutureAlthough some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.
Latest:
Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue SarcomasPatricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.
Latest:
Dr Levy on Multidisciplinary Treatment in Lung Cancer CareBenjamin Levy, MD, discusses the utility of multidisciplinary treatment in lung cancer care.
Latest:
Looking Towards The Future of HR+/HER2- Breast CancerThe expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.
Latest:
Dr Cecchini on the Results of the PROSPECT Trial in Rectal CancerMichael Cecchini, MD, discusses the phase 3 PROSPECT trial of neoadjuvant chemoradiation vs neoadjuvant fluorouracil, leucovorin, and oxaliplatin chemotherapy with selective use of chemoradiation, followed by total mesorectal excision in patients with locally advanced rectal cancer, and how this regimen may fit into the current treatment landscape for rectal cancer.
Latest:
Dr. Zhu on Treatment Strategies for Node-Positive Prostate CancerJason Zhu, MD, discusses treatment strategies for patients with node-positive prostate cancer.
Latest:
Exciting NSCLC Data Updates from ESMO 2022The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
Latest:
Dr. Zhen on Future Research Efforts in Neuroendocrine CarcinomasDavid Zhen, MD, discusses future research efforts in poorly differentiated small cell neuroendocrine carcinomas.
Latest:
Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPCJoshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.
Latest:
Dr. Rotroff on Biomarkers Associated With the Risk of Peripheral Neuropathy in Breast CancerDaniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.
Latest:
Gulf South Clinical Trials Network Named a Spoke in the ARPA-H Customer Experience Catalyst HubThe Gulf South Clinical Trials Network has been named a spoke in the ARPA-H Customer Experience Hub, one of 3 regional hubs that comprise ARPANET-H.
